Non-Hodgkin's lymphomas, version 4.2014

Andrew D. Zelenetz; Leo I. Gordon; William G. Wierda; Jeremy S. Abramson; Ranjana H. Advani; C. Babis Andreadis; Nancy Bartlett; John C. Byrd; Myron S. Czuczman; Luis E. Fayad; Richard I. Fisher; Martha J. Glenn; Nancy Lee Harris; Richard T. Hoppe; Steven M. Horwitz; Christopher R. Kelsey; Youn H. Kim; Susan Krivacic; Ann S. LaCasce; Auayporn Nademanee; Pierluigi Porcu; Oliver Press; Rachel Rabinovitch; Nishitha Reddy; Erin Reid; Ayman A. Saad; Lubomir Sokol; Lode J. Swinnen; Christina Tsien; Julie M. Vose; Joachim Yahalom; Nadeem Zafar; Mary Dwyer; Hema Sundar

doi:10.6004/jnccn.2014.0125

Non-Hodgkin's lymphomas, version 4.2014

Andrew D. Zelenetz
, Leo I. Gordon
, William G. Wierda
, Jeremy S. Abramson
, Ranjana H. Advani
, C. Babis Andreadis
, Nancy Bartlett
, John C. Byrd
, Myron S. Czuczman
, Luis E. Fayad
, Richard I. Fisher
, Martha J. Glenn
, Nancy Lee Harris
, Richard T. Hoppe
, Steven M. Horwitz
, Christopher R. Kelsey
, Youn H. Kim
, Susan Krivacic
, Ann S. LaCasce
, Auayporn Nademanee

Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Ayman A. Saad, Lubomir Sokol, Lode J. Swinnen, Christina Tsien, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, Hema Sundar

Research output: Contribution to journal › Review article › peer-review

108 Scopus citations

Abstract

Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Mantle cell lymphoma (MCL) accounts for approximately 6% of all newly diagnosed NHL cases. Radiation therapy with or without systemic therapy is a reasonable approach for the few patients who present with early-stage disease. Rituximab-based chemoimmunotherapy followed by high-dose therapy and autologous stem cell rescue (HDT/ASCR) is recommended for patients presenting with advanced-stage disease. Induction therapy followed by rituximab maintenance may provide extended disease control for those who are not candidates for HDT/ASCR. Ibrutinib, a Bruton tyrosine kinase inhibitor, was recently approved for the treatment of relapsed or refractory disease. This manuscript discusses the recommendations outlined in the NCCN Guidelines for NHL regarding the diagnosis and management of patients with MCL.

Original language	English
Pages (from-to)	1282-1303
Number of pages	22
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	12
Issue number	9
DOIs	https://doi.org/10.6004/jnccn.2014.0125
State	Published - Sep 1 2014

Bibliographical note

Publisher Copyright:
Copyright © 2014 by the National Comprehensive Cancer Network. All rights reserved.

Funding

Funders	Funder number
National Childhood Cancer Registry – National Cancer Institute	P30CA006973

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2014.0125

Cite this

Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Byrd, J. C., Czuczman, M. S., Fayad, L. E., Fisher, R. I., Glenn, M. J., Harris, N. L., Hoppe, R. T., Horwitz, S. M., Kelsey, C. R., Kim, Y. H., Krivacic, S., LaCasce, A. S., ... Sundar, H. (2014). Non-Hodgkin's lymphomas, version 4.2014. JNCCN Journal of the National Comprehensive Cancer Network, 12(9), 1282-1303. https://doi.org/10.6004/jnccn.2014.0125

@article{79cd620ce88448b0bdfe95aeab14103c,

title = "Non-Hodgkin's lymphomas, version 4.2014",

abstract = "Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Mantle cell lymphoma (MCL) accounts for approximately 6\% of all newly diagnosed NHL cases. Radiation therapy with or without systemic therapy is a reasonable approach for the few patients who present with early-stage disease. Rituximab-based chemoimmunotherapy followed by high-dose therapy and autologous stem cell rescue (HDT/ASCR) is recommended for patients presenting with advanced-stage disease. Induction therapy followed by rituximab maintenance may provide extended disease control for those who are not candidates for HDT/ASCR. Ibrutinib, a Bruton tyrosine kinase inhibitor, was recently approved for the treatment of relapsed or refractory disease. This manuscript discusses the recommendations outlined in the NCCN Guidelines for NHL regarding the diagnosis and management of patients with MCL.",

author = "Zelenetz, \{Andrew D.\} and Gordon, \{Leo I.\} and Wierda, \{William G.\} and Abramson, \{Jeremy S.\} and Advani, \{Ranjana H.\} and Andreadis, \{C. Babis\} and Nancy Bartlett and Byrd, \{John C.\} and Czuczman, \{Myron S.\} and Fayad, \{Luis E.\} and Fisher, \{Richard I.\} and Glenn, \{Martha J.\} and Harris, \{Nancy Lee\} and Hoppe, \{Richard T.\} and Horwitz, \{Steven M.\} and Kelsey, \{Christopher R.\} and Kim, \{Youn H.\} and Susan Krivacic and LaCasce, \{Ann S.\} and Auayporn Nademanee and Pierluigi Porcu and Oliver Press and Rachel Rabinovitch and Nishitha Reddy and Erin Reid and Saad, \{Ayman A.\} and Lubomir Sokol and Swinnen, \{Lode J.\} and Christina Tsien and Vose, \{Julie M.\} and Joachim Yahalom and Nadeem Zafar and Mary Dwyer and Hema Sundar",

year = "2014",

month = sep,

day = "1",

doi = "10.6004/jnccn.2014.0125",

language = "English",

volume = "12",

pages = "1282--1303",

number = "9",

}

Zelenetz, AD, Gordon, LI, Wierda, WG, Abramson, JS, Advani, RH, Andreadis, CB, Bartlett, N, Byrd, JC, Czuczman, MS, Fayad, LE, Fisher, RI, Glenn, MJ, Harris, NL, Hoppe, RT, Horwitz, SM, Kelsey, CR, Kim, YH, Krivacic, S, LaCasce, AS, Nademanee, A, Porcu, P, Press, O, Rabinovitch, R, Reddy, N, Reid, E, Saad, AA, Sokol, L, Swinnen, LJ, Tsien, C, Vose, JM, Yahalom, J, Zafar, N, Dwyer, M & Sundar, H 2014, 'Non-Hodgkin's lymphomas, version 4.2014', JNCCN Journal of the National Comprehensive Cancer Network, vol. 12, no. 9, pp. 1282-1303. https://doi.org/10.6004/jnccn.2014.0125

TY - JOUR

T1 - Non-Hodgkin's lymphomas, version 4.2014

AU - Zelenetz, Andrew D.

AU - Gordon, Leo I.

AU - Wierda, William G.

AU - Abramson, Jeremy S.

AU - Advani, Ranjana H.

AU - Andreadis, C. Babis

AU - Bartlett, Nancy

AU - Byrd, John C.

AU - Czuczman, Myron S.

AU - Fayad, Luis E.

AU - Fisher, Richard I.

AU - Glenn, Martha J.

AU - Harris, Nancy Lee

AU - Hoppe, Richard T.

AU - Horwitz, Steven M.

AU - Kelsey, Christopher R.

AU - Kim, Youn H.

AU - Krivacic, Susan

AU - LaCasce, Ann S.

AU - Nademanee, Auayporn

AU - Porcu, Pierluigi

AU - Press, Oliver

AU - Rabinovitch, Rachel

AU - Reddy, Nishitha

AU - Reid, Erin

AU - Saad, Ayman A.

AU - Sokol, Lubomir

AU - Swinnen, Lode J.

AU - Tsien, Christina

AU - Vose, Julie M.

AU - Yahalom, Joachim

AU - Zafar, Nadeem

AU - Dwyer, Mary

AU - Sundar, Hema

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Mantle cell lymphoma (MCL) accounts for approximately 6% of all newly diagnosed NHL cases. Radiation therapy with or without systemic therapy is a reasonable approach for the few patients who present with early-stage disease. Rituximab-based chemoimmunotherapy followed by high-dose therapy and autologous stem cell rescue (HDT/ASCR) is recommended for patients presenting with advanced-stage disease. Induction therapy followed by rituximab maintenance may provide extended disease control for those who are not candidates for HDT/ASCR. Ibrutinib, a Bruton tyrosine kinase inhibitor, was recently approved for the treatment of relapsed or refractory disease. This manuscript discusses the recommendations outlined in the NCCN Guidelines for NHL regarding the diagnosis and management of patients with MCL.

AB - Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Mantle cell lymphoma (MCL) accounts for approximately 6% of all newly diagnosed NHL cases. Radiation therapy with or without systemic therapy is a reasonable approach for the few patients who present with early-stage disease. Rituximab-based chemoimmunotherapy followed by high-dose therapy and autologous stem cell rescue (HDT/ASCR) is recommended for patients presenting with advanced-stage disease. Induction therapy followed by rituximab maintenance may provide extended disease control for those who are not candidates for HDT/ASCR. Ibrutinib, a Bruton tyrosine kinase inhibitor, was recently approved for the treatment of relapsed or refractory disease. This manuscript discusses the recommendations outlined in the NCCN Guidelines for NHL regarding the diagnosis and management of patients with MCL.

UR - https://www.scopus.com/pages/publications/84907289619

UR - https://www.scopus.com/pages/publications/84907289619#tab=citedBy

U2 - 10.6004/jnccn.2014.0125

DO - 10.6004/jnccn.2014.0125

M3 - Review article

C2 - 25190696

AN - SCOPUS:84907289619

SN - 1540-1405

VL - 12

SP - 1282

EP - 1303

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 9

ER -

Non-Hodgkin's lymphomas, version 4.2014

Abstract

Bibliographical note

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this